Abbott Dx Revenues Rise 4 Percent in Q2 on Strong Core Lab and Point-of-Care Growth

Jul 20, 2017

|

This article has been updated to include additional comments from Abbott's earnings call.

NEW YORK (GenomeWeb) – Abbott today said that its Diagnostics business grew sales 4 percent year over year in the second quarter, driven in part by strong growth in for its core laboratory and point-of-care tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Abbott Dx Revenues Rise 4 Percent in Q2 on Strong Core Lab and Point-of-Care Growth

To read the full story....

Breaking News

Somalogic Closes $121M Series A Funding

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Tempus Gets CE Mark for xT Tumor Sequencing Assay

BTIG Downgrades Fulgent Genetics from Buy to Neutral

What's Popular?

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

Abviris Developing Blood-Based Serology Test For HPV-Related Cancers

Sponsorships